Role of Mitochondrial Dysfunction in Related Diseases-A Review

Main Article Content

Zainab Yousaf
Mobashra Mustafa
Abdul Mannan
Mahnoor Rao
Rabia Basri Javaid
Ammara Hussain Siddiqi

Abstract

Background: Mitochondrial dysfunction (MD) is increasingly recognized for its role in a wide array of diseases, extending beyond primary mitochondrial diseases (PMDs) to include secondary mitochondrial diseases (SMDs) and a broad spectrum of neurodegenerative, cardiovascular, metabolic, and oncological disorders. This growing awareness underscores the need for a comprehensive review of the mechanisms underlying MD, its clinical implications, and emerging therapeutic strategies.


Objective: To synthesize current knowledge on the pathogenesis of diseases associated with MD, delineate the distinction between PMDs and SMDs, explore the genetic and environmental factors contributing to MD, and assess the potential of novel therapeutic approaches targeting mitochondrial dysfunction.


Methods: A narrative review was conducted through a structured search of PubMed, Scopus, Web of Science, and Google Scholar, focusing on articles published up to April 2023. Keywords related to mitochondrial dysfunction and its implications across various diseases were used to identify relevant studies. Inclusion criteria targeted original research, reviews, and meta-analyses published in English that contributed to understanding MD's role in disease pathogenesis and treatment. Data extraction and synthesis were performed to highlight key findings, mechanisms, and therapeutic strategies.


Results: The review emphasizes the critical role of mitochondrial dysfunction in the pathogenesis of a wide range of diseases. It identifies specific mtDNA mutations contributing to PMDs and highlights how SMDs arise from mitochondrial impairment secondary to other conditions. The synthesis of findings points to oxidative stress, impaired ATP production, and altered mitochondrial dynamics as central to MD's impact on cellular and systemic health. Additionally, the review explores emerging therapies, including mitochondrial-targeted antioxidants, gene therapy, and metabolic interventions, underscoring their potential in managing MD-related diseases.


Conclusion: Mitochondrial dysfunction is a pivotal factor in the etiology of numerous diseases, with genetic mutations and environmental influences contributing to its development and progression. Understanding these complex mechanisms is essential for devising effective therapeutic interventions. While significant advances have been made, further research is needed to fully exploit the therapeutic potential of targeting mitochondrial dysfunction.

Article Details

How to Cite
Yousaf, Z., Mustafa, M., Mannan, A., Rao, M., Javaid, R. B., & Siddiqi, A. H. (2024). Role of Mitochondrial Dysfunction in Related Diseases-A Review. Journal of Health and Rehabilitation Research, 4(1), 1328–1333. https://doi.org/10.61919/jhrr.v4i1.604
Section
Articles
Author Biographies

Zainab Yousaf, Farooq Hospital Westwood Lahore Pakistan.

B.S.C (Hons) MLT, MPhil (Human genetics & Molecular biology), Lab Manager, Department of Pathology, Farooq Hospital Westwood, Lahore, Pakistan.

Mobashra Mustafa, University of Veterinary and Animals Sciences Lahore Pakistan.

BS (Hons) Microbiology, MPhil (Microbiology), PhD. scholar (Microbiology), University of Veterinary and Animals Sciences, Lahore, Pakistan.

Abdul Mannan, Ibn-e-Sina Laboratory Collection Center Faisalabad Pakistan.

BS (Hons) Biotechnology, MPhil (Human Genetics & Molecular biology), Ibn-e-Sina Laboratory Collection Center, Faisalabad, Pakistan.

Mahnoor Rao, University of Veterinary and Animals Sciences Lahore Pakistan.

BS (Hons) Microbiology, MPhil (Microbiology), PhD. Scholar (Microbiology), University of Veterinary and Animals Sciences Lahore, Pakistan.

Rabia Basri Javaid, University of Health Sciences Lahore Pakistan.

BS (Hons) Biotechnology, MPhil (Human genetics & Molecular biology), University of Health Sciences, Lahore, Pakistan.

Ammara Hussain Siddiqi, University of Central Punjab Lahore Pakistan.

B.S.C (Hons) MLT, MS (Microbiology), University of Central Punjab, Lahore, Pakistan.

References

Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards mitochondria based therapeutic strategies. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(5):1066-77.

Jafri MS, Dudycha SJ, O'Rourke B. Cardiac energy metabolism: models of cellular respiration. Annual review of biomedical engineering. 2001;3(1):57-81.

Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. Nature reviews Molecular cell biology. 2018;19(11):713-30.

Turrens JF. Mitochondrial formation of reactive oxygen species. The Journal of physiology. 2003;552(2):335-44.

Abate M, Festa A, Falco M, Lombardi A, Luce A, Grimaldi A, et al., editors. Mitochondria as playmakers of apoptosis, autophagy and senescence. Seminars in cell & developmental biology; 2020: Elsevier.

Dadsena S, Zollo C, García-Sáez AJ. Mechanisms of mitochondrial cell death. Biochemical Society Transactions. 2021;49(2):663-74.

Schapira AH. Mitochondrial disease. The Lancet. 2006;368(9529):70-82.

Niyazov DM, Kahler SG, Frye RE. Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. Molecular syndromology. 2016;7(3):122-37.

Stewart JB, Larsson N-G. Keeping mtDNA in shape between generations. PLoS genetics. 2014;10(10):e1004670.

Boesch P, Weber-Lotfi F, Ibrahim N, Tarasenko V, Cosset A, Paulus F, et al. DNA repair in organelles: pathways, organization, regulation, relevance in disease and aging. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2011;1813(1):186-200.

Smeets HJ, Sallevelt SC, Dreesen JC, de Die‐Smulders CE, de Coo IF. Preventing the transmission of mitochondrial DNA disorders using prenatal or preimplantation genetic diagnosis. Annals of the New York Academy of Sciences. 2015;1350(1):29-36.

Sobenin IA, Mitrofanov KY, Zhelankin AV, Sazonova MA, Postnov AY, Revin VV, et al. Quantitative assessment of heteroplasmy of mitochondrial genome: perspectives in diagnostics and methodological pitfalls. BioMed research international. 2014;2014.

Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 2010;10(1):12-31.

Guha M, Avadhani NG. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion. 2013;13(6):577-91.

Chen C, Chen Y, Guan M-X. A peep into mitochondrial disorder: multifaceted from mitochondrial DNA mutations to nuclear gene modulation. Protein & cell. 2015;6(12):862-70.

Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW, et al. Prevalence of mitochondrial DNA disease in adults. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2008;63(1):35-9.

Spinazzola A, editor Mitochondrial DNA mutations and depletion in pediatric medicine. Seminars in Fetal and Neonatal Medicine; 2011: Elsevier.

Poulton J, Chiaratti MR, Meirelles FV, Kennedy S, Wells D, Holt IJ. Transmission of mitochondrial DNA diseases and ways to prevent them. PLoS genetics. 2010;6(8):e1001066.

Mancuso M, Vives-Bauza C, Filosto M, Marti R, Solano A, Montoya J, et al. A mitochondrial DNA duplication as a marker of skeletal muscle specific mutations in the mitochondrial genome. Journal of Medical Genetics. 2004;41(6):e73-e.

Vu TH, Hirano M, DiMauro S. Mitochondrial diseases. Neurologic clinics. 2002;20(3):809-39.

Carrozzo R, Hirano M, Fromenty B, Casali C, Santorelli F, Bonilla E, et al. Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses. Neurology. 1998;50(1):99-106.

Zhang Y, Avalos JL. Traditional and novel tools to probe the mitochondrial metabolism in health and disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2017;9(2):e1373.

Sofou K, De Coo IF, Isohanni P, Ostergaard E, Naess K, De Meirleir L, et al. A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet journal of rare diseases. 2014;9(1):1-16.

DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscular disorders. 2005;15(4):276-86.

Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283(5407):1482-8.

Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial diseases. Nature reviews Disease primers. 2016;2(1):1-22.

Appenzeller S, Balling R, Barisic N, Baulac S, Caglayan H, Craiu D, et al. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. The American Journal of Human Genetics. 2014;95(4):360-70.

Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. 2018.

Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nature Reviews Neurology. 2019;15(1):40-52.

Archer SL. Mitochondrial dynamics—mitochondrial fission and fusion in human diseases. New England Journal of Medicine. 2013;369(23):2236-51.

Yoon Y GC, Jhun B, Yu T. Mitochondrial dynamics in diabetes. Antioxid Redox SignaL. 2011;14:439-457.

Ong SB HA, Hausenloy DJ. Mitochondrial dynamics in cardiovascular health and disease. Antioxid Redox Signal. 2013;19:400-414.

Zhan M BC, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int 2013;83:568-581.

Jiang Z WW, Perry G, Zhu X, Wang X. Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:14.

Ashwal S, Swaiman KF, Ferriero DM, Schor NF. Swaiman's pediatric neurology: principles and practice. (No Title). 2017.

Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders. 2018;28(3):197-207.

Pandolfo M. Friedreich ataxia. Archives of neurology. 2008;65(10):1296-303.

Wang R, He J, Li J-J, Ni W, Wu Z-Y, Chen W-J, et al. Clinical and genetic spectra in a series of Chinese patients with Charcot–Marie–Tooth disease. Clinica Chimica Acta. 2015;451:263-70.

De Sandre-Giovannoli A, Delague V, Hamadouche T, Chaouch M, Krahn M, Boccaccio I, et al. Homozygosity mapping of autosomal recessive demyelinating Charcot-Marie-Tooth neuropathy (CMT4H) to a novel locus on chromosome 12p11. 21-q13. 11. Journal of medical genetics. 2005;42(3):260-5.

Reid E. Pure hereditary spastic paraplegia. Journal of medical genetics. 1997;34(6):499.

Schüle R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, et al. Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Annals of neurology. 2016;79(4):646-58.

Leggio L, Gasbarrini G, Addolorato G. Wilson's disease. The Lancet. 2007;369(9565):902.

Schon KR, Ratnaike, T., van den Ameele, J. Mitochondrial diseases: a diagnostic revolution. Trends in Genetics. Horvath, R and Chinnery,. 2020;6(9), pp.702-717.

Stenton SLaP, H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56.

Failla M CC, Aoki F. Increased bioavailability of ubiquinol compared to that of ubiquinone is due to more efficient micellarization during digestion and greater GSH-dependent uptake and basolateral secretion by Caco-2 cells. J Agric Food Chem. 2014; 62:7174-7182

Wallace, C D. Mitochondrial DNA mutations in disease and aging. Environmental and Molecular Mutagenesis. 2013;51(5):10.

Schon, Eric A., Manfredi, Giovanni. Neuronal Mitochondrial Metabolism: A Review. Journal of Neurochemistry. 2013;109(S1):9.

Chowdhury, Salim. Mitochondrial Dysfunction in Aging and Alzheimer's Disease: Progress and Prospects. Biomolecules. 2020;10(3):364.